Julie Rubinstein exercised options at $12.14 per share on October 9, 12 and 13, 2026, under a trading plan adopted November 18, 2025.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) COO Julie Rubinstein sold 11,881 shares of the firm

Vea los precios de cotización de acciones de ADPT de Adaptive Biotechnologies Corp., información financiera, pronósticos en tiempo real y noticias de la compañía de CNN.

Shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) have received an average rating of "Moderate Buy" from the eight ratings firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given

Adaptive Biotechnologies is estimated to report Q3 2026 earnings on November 4, 2026. See the scheduled call time, analyst EPS and revenue estimates, and past results for ADPT at MarketBeat.

President and COO Julie Rubinstein exercised vested options and sold shares October 6–8, 2026, under a trading plan adopted November 18, 2025.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) insider Susan Bobulsky sold 6,444 shares of the stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $30.00, for a total transaction of $193,320.00. Following the completion of the transaction, the insider owned 389,350 shares of the company